Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Vabysmo (faricimab) for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). This recommendation is based on positive outcomes from four phase III trials, where over 60% of patients could extend treatment intervals to every four months while improving vision. If approved, Vabysmo will be the first new treatment mechanism in over a decade for nAMD and DME in the EU, potentially benefiting millions suffering from these conditions.
Roche will present its innovative diagnostic solutions at the 2022 AACC Scientific Meeting in Chicago, from July 24-28. The exhibit booth will showcase systems that improve lab efficiencies and patient care, including the cobas® pro and cobas® pulse solutions. Roche will also introduce the Idea Lab series, focusing on key healthcare topics such as health equity and staffing pressures. The booth will feature 18 systems and 11 interactive workshops, aiming to address current lab challenges and enhance clinical outcomes.
Roche (OTCQX: RHHBY) has announced significant leadership changes as Christoph Franz will not seek re-election as Chairman at the AGM on March 14, 2023. The Board intends to propose Severin Schwan as the new Chairman. Additionally, Thomas Schinecker, currently CEO of the Diagnostics Division, will assume the role of CEO on March 15, 2023, succeeding Schwan. Franz, who has been with Roche since 2011, highlighted the company's achievements and stability in shareholder structure during his tenure, particularly its response to the COVID-19 pandemic.
Roche reported a 5% increase in group sales, reaching CHF 32.3 billion in the first half of 2022, driven by strong demand for new medicines and diagnostics. The Pharmaceuticals Division grew 3%, with significant contributions from products like Hemlibra and Ocrevus. The Diagnostics Division saw an 11% rise, bolstered by COVID-19 test sales. Net income rose by 12% to CHF 9.2 billion. Roche confirmed its outlook for 2022, anticipating stable sales growth while facing challenges from declining COVID-19 medicine sales and biosimilar competition, projecting a potential CHF 2.5 billion revenue loss from biosimilars.
Roche has received FDA Breakthrough Device Designation for its Elecsys Amyloid Plasma Panel, aimed at early detection of Alzheimer's disease. This innovative blood test measures biomarkers to facilitate timely diagnosis, addressing the urgent need, as up to 75% of symptomatic patients remain undiagnosed. The panel combines pTau 181 and APOE E4 assays, providing a non-invasive alternative to traditional methods. It enhances patient assessment, potentially streamlining access to confirmatory tests like PET scans, ultimately improving care for over 55 million people affected by dementia worldwide.
Roche has launched the Elecsys HCV Duo, a groundbreaking immunoassay for the simultaneous detection of hepatitis C virus (HCV) antigen and antibodies, available in CE Mark countries as of July 18, 2022. This dual detection enables earlier diagnosis and intervention in patients, aiming to curb disease progression and transmission. Approximately 58 million globally live with chronic HCV, with 290,000 annual fatalities, highlighting the urgent need for improved testing. The Elecsys HCV Duo is expected to enhance healthcare efficiency while addressing significant gaps in testing accessibility.
On July 14, 2022, Roche (OTCQX: RHHBY) released updated results from the phase III APHINITY study, showcasing the efficacy of the Perjeta-based regimen in treating HER2-positive early breast cancer. With a median follow-up of 8.4 years, a 28% reduction in recurrence or death was observed in lymph node-positive patients, translating to a 4.9% absolute benefit. While the safety profile remained consistent, overall survival data are still immature. The regimen is approved in over 100 countries and represents a significant advancement in cancer treatment for high-risk patients.
Roche (OTCQX: RHHBY) announced promising two-year results from the TENAYA and LUCERNE studies, highlighting the effectiveness of Vabysmo (faricimab) in treating neovascular age-related macular degeneration (nAMD). Over 60% of patients could be treated every four months, an increase from 45% at year one, while requiring a median of 10 injections compared to 15 for aflibercept. The treatment showed comparable vision gains and no new safety concerns, reinforcing its favorable benefit-risk profile. These results support Vabysmo's role in the evolving standards of care for retinal diseases.
Roche announced positive results from the phase III HAVEN 6 study for Hemlibra (emicizumab), showing that 66.7% of participants with moderate or mild haemophilia A experienced zero treated bleeds at an average follow-up of 55.6 weeks. The study also highlighted Hemlibra's consistent safety profile, with no new safety signals detected. Hemlibra is currently approved for use in over 110 countries for those with haemophilia A, including various treatment options to enhance patient outcomes.
Genentech announced positive results from the Phase III HAVEN 6 study of Hemlibra (emicizumab-kxwh), showing 66.7% of participants with moderate or mild hemophilia A experienced zero treated bleeds over a median follow-up of 55.6 weeks. The study demonstrated Hemlibra's favorable safety profile, with no new safety signals reported. Hemlibra is approved for treating hemophilia A in over 110 countries. The findings will support a submission to the European Medicines Agency for expanding the label to include non-severe hemophilia A patients.